SOCS and diabetes-ups and downs of a turbulent relationship

Cell Biochemistry and Function

Volumn 31, Issue 3, 2013, Pages 181-195

  Suchy, Dariusz ^a   Labuzek, Krzysztof ^a   Machnik, Grzegorz ^a   Kozlowski, Michal ^a   Okopień, Boguslaw ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Beta cells; Expression; Insulin resistance; SOCS; Type 1 diabetes; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 [(4 ANILINO 2 METHOXYPHENYL)SULFAMOYL] 2 THENOIC ACID METHYL ESTER; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ANGIOTENSIN II; EXENDIN 4; KERATINOCYTE DERIVED CHEMOKINE; LEPTIN; ONCOSTATIN M; RESISTIN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 2; SUPPRESSOR OF CYTOKINE SIGNALING 3; SUPPRESSOR OF CYTOKINE SIGNALING 6; SUPPRESSOR OF CYTOKINE SIGNALING 7; UNCLASSIFIED DRUG;

ANTIDIABETIC ACTIVITY; ARTICLE; CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIET; DISEASE ASSOCIATION; FATTY ACID SYNTHESIS; GLUCOSE METABOLISM; GLYCOGEN SYNTHESIS; GRAFT SURVIVAL; HEPATITIS C VIRUS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAUTERINE GROWTH RETARDATION; MODULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SURVIVAL;

ANIMALS; CARDIOMYOPATHIES; CYTOKINES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84876076756     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.2940     Document Type: Article

References (106)

1. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010; 464: 1293-1300.
2. Santangelo C, Scipioni A, Marselli L, Marchetti P, Dotta F. Suppressor of cytokine signaling gene expression in human pancreatic islets: modulation by cytokines. Eur J Endocrinol 2005; 152: 485-489.
3. Lebrun P, Van Obberghen E. SOCS proteins causing trouble in insulin action. Acta Physiol (Oxf) 2008; 192: 29-36.
4. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-481.
5. Blach-Olszewska Z. Control of over-activated innate immunity. Postepy Hig Med Dosw (Online) 2006; 60: 201-208.
6. Elliott J, Johnston JA. SOCS: role in inflammation, allergy and homeostasis. Trends Immunol 2004; 25: 434-440.
7. Larsen L, Röpke C. Suppressors of cytokine signalling: SOCS. APMIS 2002; 110: 833-844.
8. Piessevaux J, Lavens D, Peelman F, Tavernier J. The many faces of the SOCS box. Cytokine Growth Factor Rev 2008; 19: 371-381.
9. Venieratos PD, Drossopoulou GI, Kapodistria KD, Tsilibary EC, Kitsiou PV. High glucose induces suppression of insulin signalling and apoptosis via upregulation of endogenous IL-1beta and suppressor of cytokine signalling-1 in mouse pancreatic beta cells. Cell Signal 2010; 22: 791-800.
10. Ni R, Ihara K, Miyako K, et al. Association study of polymorphisms in SOCS family genes with type 1 diabetes mellitus. Int J Immunogenet 2006; 33: 7-10.
11. Chong MM, Thomas HE, Kay TW. Gamma-interferon signaling in pancreatic beta-cells is persistent but can be terminated by overexpression of suppressor of cytokine signaling-1. Diabetes 2001; 50: 2744-2751.
12. Cottet S, Dupraz P, Hamburger F, Dolci W, Jaquet M, Thorens B. SOCS-1 protein prevents Janus kinase/STAT-dependent inhibition of beta cell insulin gene transcription and secretion in response to interferon-gamma. J Biol Chem 2001; 276: 25862-25870.
13. Chong MM, Chen Y, Darwiche R, et al. Suppressor of cytokine signaling-1 overexpression protects pancreatic beta cells from CD8+ T cell-mediated autoimmune destruction. J Immunol 2004; 172: 5714-5721.
14. Zaitseva II, Hultcrantz M, Sharoyko V, Flodström-Tullberg M, Zaitsev SV, Berggren PO. Suppressor of cytokine signaling-1 inhibits caspase activation and protects from cytokine-induced beta cell death. Cell Mol Life Sci 2009; 66: 3787-3795.
15. Flodström-Tullberg M, Yadav D, Hägerkvist R, et al. Target cell expression of suppressor of cytokine signaling-1 prevents diabetes in the NOD mouse. Diabetes 2003; 52: 2696-2700.
16. Barral AM, Thomas HE, Ling EM, et al. SOCS-1 protects from virally-induced CD8 T cell mediated type 1 diabetes. J Autoimmun 2006; 27: 166-173.
17. Dudek NL, Thomas HE, Mariana L, et al. Cytotoxic T-cells from T-cell receptor transgenic NOD8.3 mice destroy beta-cells via the perforin and Fas pathways. Diabetes 2006; 55: 2412-2418.
18. McKenzie MD, Dudek NL, Mariana L, et al. Perforin and Fas induced by IFNgamma and TNFalpha mediate beta cell death by OT-I CTL. Int Immunol 2006; 18: 837-846.
19. Flodström M, Maday A, Balakrishna D, Cleary MM, Yoshimura A, Sarvetnick N. Target cell defense prevents the development of diabetes after viral infection. Nat Immunol 2002; 3: 373-382.
20. Chong MM, Thomas HE, Kay TW. Suppressor of cytokine signaling-1 regulates the sensitivity of pancreatic beta cells to tumor necrosis factor. J Biol Chem 2002; 277: 27945-27952.
21. Bruun C, Heding PE, Rønn SG, et al. Suppressor of cytokine signalling-3 inhibits tumor necrosis factor-alpha induced apoptosis and signalling in beta cells. Mol Cell Endocrinol 2009; 311: 32-38.
22. Karlsen AE, Rønn SG, Lindberg K, et al. Suppressor of cytokine signaling 3 (SOCS-3) protects beta -cells against interleukin-1beta - and interferon-gamma -mediated toxicity. Proc Nat Acad Sci USA 2001; 98: 12191-12196.
23. Rønn SG, Börjesson A, Bruun C, et al. Suppressor of cytokine signalling-3 expression inhibits cytokine-mediated destruction of primary mouse and rat pancreatic islets and delays allograft rejection. Diabetologia 2008; 51: 1873-1882.
24. Jacobsen ML, Rønn SG, Bruun C, et al. IL-1beta-induced chemokine and Fas expression are inhibited by suppressor of cytokine signalling-3 in insulin-producing cells. Diabetologia 2009; 52: 281-288.
25. Mori H, Shichita T, Yu Q, et al. Suppression of SOCS3 expression in the pancreatic beta-cell leads to resistance to type 1 diabetes. Biochem Biophys Res Commun 2007; 359: 952-958.
26. Lee JH, Yang SH, Oh JM, Lee MG. Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus. J Pharm Pharmacol 2010; 62: 1-23.
27. Lindberg K, Rønn SG, Tornehave D, et al. Regulation of pancreatic beta-cell mass and proliferation by SOCS-3. J Mol Endocrinol 2005; 35: 231-243.
28. Börjesson A, Rønn SG, Karlsen AE, Billestrup N, Sandler S. β-cell specific overexpression of suppressor of cytokine signalling-3 does not protect against multiple low dose streptozotocin induced type 1 diabetes in mice. Immunol Lett 2011; 136: 74-79.
29. Emanuelli B, Glondu M, Filloux C, Peraldi P, Van Obberghen E. The potential role of SOCS-3 in the interleukin-1beta-induced desensitization of insulin signaling in pancreatic beta-cells. Diabetes 2004; 53(Suppl 3): S97-S103.
30. Laubner K, Kieffer TJ, Lam NT, Niu X, Jakob F, Seufert J. Inhibition of preproinsulin gene expression by leptin induction of suppressor of cytokine signaling 3 in pancreatic beta-cells. Diabetes 2005; 54: 3410-3417.
31. Puff R, Dames P, Weise M, Göke B, Parhofer K, Lechner A. No non-redundant function of suppressor of cytokine signaling 2 in insulin producing β-cells. Islets 2010; 2: 252-257.
32. Lebrun P, Cognard E, Gontard P, et al. The suppressor of cytokine signalling 2 (SOCS2) is a key repressor of insulin secretion. Diabetologia 2010; 53: 1935-1946.
33. Suo GJ, Qin J, Zhong CP, Zhao ZX. Suppressor of cytokine signaling 1 inhibits apoptosis of islet grafts through caspase 3 and apoptosis-inducing factor pathways in rats. Transplant Proc 2010; 42: 2658-2661.
34. Qin J, Jiao Y, Chen X, Zhou S, Liang C, Zhong C. Overexpression of suppressor of cytokine signaling 1 in islet grafts results in anti-apoptotic effects and prolongs graft survival. Life Sci 2009; 84: 810-816.
35. Solomon M, Flodström-Tullberg M, Sarvetnick N. Beta-cell specific expression of suppressor of cytokine signaling-1 (SOCS-1) delays islet allograft rejection by down-regulating Interferon Regulatory Factor-1 (IRF-1) signaling. Transpl Immunol 2011; 24: 181-188.
36. Solomon M, Flodström-Tullberg M, Sarvetnick N. Differences in suppressor of cytokine signaling-1 (SOCS-1) expressing islet allograft destruction in normal BALB/c and spontaneously-diabetic NOD recipient mice. Transplantation 2005; 79: 1104-1109.
37. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004; 24: 5434-5446.
38. Youngren JF. Regulation of insulin receptor function. Cell Mol Life Sci 2007; 64: 873-891.
39. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002; 277: 42394-42398.
40. Wang Y, Nishina PM, Naggert JK. Degradation of IRS1 leads to impaired glucose uptake in adipose tissue of the type 2 diabetes mouse model TALLYHO/Jng. J Endocrinol 2009; 203: 65-74.
41. Ueki K, Kondo T, Tseng YH, Kahn CR. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Nat Acad Sci USA 2004; 101: 10422-10427.
42. Ueki K, Kadowaki T, Kahn CR. Role of suppressors of cytokine signaling SOCS-1 and SOCS-3 in hepatic steatosis and the metabolic syndrome. Hepatol Res 2005; 33: 185-192.
43. Zhang Y, Zhou B, Zhang F, et al. Amyloid-β induces hepatic insulin resistance by activating JAK2/STAT3/SOCS-1 signaling pathway. Diabetes 2012; 61: 1434-1443.
44. Jamieson E, Chong MM, Steinberg GR, et al. Socs1 deficiency enhances hepatic insulin signaling. J Biol Chem 2005; 280: 31516-31521.
45. Sachithanandan N, Graham KL, Galic S, et al. Macrophage deletion of SOCS1 increases sensitivity to LPS and palmitic acid and results in systemic inflammation and hepatic insulin resistance. Diabetes 2011; 60: 2023-2031.
46. Gylvin T, Ek J, Nolsøe R, et al. Functional SOCS1 polymorphisms are associated with variation in obesity in whites. Diabetes Obes Metab 2009; 11: 196-203.
47. Emanuelli B, Macotela Y, Boucher J, Ronald Kahn C. SOCS-1 deficiency does not prevent diet-induced insulin resistance. Biochem Biophys Res Commun 2008; 377: 447-452.
48. Yang SJ, Xu CQ, Wu JW, Yang GS. SOCS3 inhibits insulin signaling in porcine primary adipocytes. Mol Cell Biochem 2010; 345: 45-52.
49. Gylvin T, Nolsøe R, Hansen T, et al. Mutation analysis of suppressor of cytokine signalling 3, a candidate gene in type 1 diabetes and insulin sensitivity. Diabetologia 2004; 47: 1273-1277.
50. Fischer-Rosinsky A, Fisher E, Kovacs P, et al. Lack of association between the tagging SNP A+930-->G of SOCS3 and type 2 diabetes mellitus: meta-analysis of four independent study populations. PLoS One 2008; 3: e3852.
51. Emanuelli B, Peraldi P, Filloux C, et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 2001; 276: 47944-47949.
52. Eguchi M, Shrivastava S, Lyakhovsky N, Kim W, Palanivel R, Sweeney G. Control of fatty acid metabolism by leptin in L6 rat myoblasts is regulated by hyperinsulinemia. J Endocrinol Invest 2007; 30: 192-199.
53. Kim JH, Bachmann RA, Chen J. Interleukin-6 and insulin resistance. Vitam Horm 2009; 80: 613-633.
54. Henkel J, Neuschäfer-Rube F, Pathe-Neuschäfer-Rube A, Püschel GP. Aggravation by prostaglandin E2 of interleukin-6-dependent insulin resistance in hepatocytes. Hepatology 2009; 50: 781-790.
55. Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003; 278: 13740-13746.
56. Lutz SZ, Hennige AM, Feil S, et al. Genetic ablation of cGMP-dependent protein kinase type I causes liver inflammation and fasting hyperglycemia. Diabetes 2011; 60: 1566-1576.
57. Rotter Sopasakis V, Larsson BM, Johansson A, Holmäng A, Smith U. Short-term infusion of interleukin-6 does not induce insulin resistance in vivo or impair insulin signalling in rats. Diabetologia 2004; 47: 1879-1887.
58. Rieusset J, Bouzakri K, Chevillotte E, et al. Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 2004; 53: 2232-2241.
59. McGillicuddy FC, Harford KA, Reynolds CM, et al. Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet-induced adipose tissue inflammation coincident with improved glucose homeostasis. Diabetes 2011; 60: 1688-1698.
60. Arruda AP, Milanski M, Coope A, et al. Low-grade hypothalamic inflammation leads to defective thermogenesis, insulin resistance, and impaired insulin secretion. Endocrinology 2011; 152: 1314-1326.
61. Neels JG, Badeanlou L, Hester KD, Samad F. Keratinocyte-derived chemokine in obesity: expression, regulation, and role in adipose macrophage infiltration and glucose homeostasis. J Biol Chem 2009; 284: 20692-20698.
62. Briancon N, McNay DE, Maratos-Flier E, Flier JS. Combined neural inactivation of suppressor of cytokine signaling-3 and protein-tyrosine phosphatase-1B reveals additive, synergistic, and factor-specific roles in the regulation of body energy balance. Diabetes 2010; 59: 3074-3084.
63. Ghanim H, Abuaysheh S, Sia CL, et al. Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care 2009; 32: 2281-2287.
64. Deopurkar R, Ghanim H, Friedman J, et al. Differential effects of cream, glucose, and orange juice on inflammation, endotoxin, and the expression of Toll-Like receptor-4 and suppressor of cytokine signaling-3. Diabetes Care 2010; 33: 991-997.
65. Pascarella S, Clément S, Guilloux K, Conzelmann S, Penin F, Negro F. Effects of hepatitis C virus on suppressor of cytokine signaling mRNA levels: comparison between different genotypes and core protein sequence analysis. J Med Virol 2011; 83: 1005-1015.
66. del Campo JA, López RA, Romero-Gómez M. Insulin resistance and response to antiviral therapy in chronic hepatitis C: mechanisms and management. Dig Dis 2010; 28: 285-293.
67. Sánchez-Solana B, Laborda J, Baladrón V. Mouse resistin modulates adipogenesis and glucose uptake in 3T3-L1 preadipocytes through the ROR1 receptor. Mol Endocrinol 2012; 26: 110-127.
68. Liu F, Qiu J, Zhang CM, Ji CB, Guo XR. Resistin inhibits rat insulinoma cell RINm5F proliferation. Zhongguo Dang Dai Er Ke Za Zhi 2010; 12: 43-46.
69. Henkel J, Gärtner D, Dorn C, et al. Oncostatin M produced in Kupffer cells in response to PGE2: possible contributor to hepatic insulin resistance and steatosis. Lab Invest 2011; 91: 1107-1117.
70. Muscogiuri G, Chavez AO, Gastaldelli A, et al. The crosstalk between insulin and renin-angiotensin-aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention. Curr Vasc Pharmacol 2008; 6: 301-312.
71. Velloso LA, Folli F, Perego L, Saad MJ. The multi-faceted cross-talk between the insulin and angiotensin II signaling systems. Diabetes Metab Res Rev 2006; 22: 98-107.
72. Shi H, Cave B, Inouye K, Bjørbaek C, Flier JS. Overexpression of suppressor of cytokine signaling 3 in adipose tissue causes local but not systemic insulin resistance. Diabetes 2006; 55: 699-707.
73. Shi H, Tzameli I, Bjørbaek C, Flier JS. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol Chem 2004; 279: 34733-34740.
74. Torisu T, Sato N, Yoshiga D, et al. The dual function of hepatic SOCS3 in insulin resistance in vivo. Genes Cells 2007; 12: 143-154.
75. Gokulakrishnan K, Mohanavalli KT, Monickaraj F, Mohan V, Balasubramanyam M. Subclinical inflammation/oxidation as revealed by altered gene expression profiles in subjects with impaired glucose tolerance and type 2 diabetes patients. Mol Cell Biochem 2009; 324: 173-181.
76. Kato H, Nomura K, Osabe D, et al. Association of single-nucleotide polymorphisms in the suppressor of cytokine signaling 2 (SOCS2) gene with type 2 diabetes in the Japanese. Genomics 2006; 87: 446-458.
77. Li L, Grønning LM, Anderson PO, et al. Insulin induces SOCS-6 expression and its binding to the p85 monomer of phosphoinositide 3-kinase, resulting in improvement in glucose metabolism. J Biol Chem 2004; 279: 34107-34114.
78. Mooney RA, Senn J, Cameron S, et al. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 2001; 276: 25889-25893.
79. Banks AS, Li J, McKeag L, et al. Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans. J Clin Invest 2005; 115: 2462-2471.
80. Jiang Y, Zhang Q, Soderland C, Steinle JJ. TNFα and SOCS3 regulate IRS-1 to increase retinal endothelial cell apoptosis. Cell Signal 2012; 24: 1086-1092.
81. Liu X, Mameza MG, Lee YS, et al. Suppressors of cytokine-signaling proteins induce insulin resistance in the retina and promote survival of retinal cells. Diabetes 2008; 57: 1651-1658.
82. Street ME, Viani I, Ziveri MA, Volta C, Smerieri A, Bernasconi S. Impairment of insulin receptor signal transduction in placentas of intra-uterine growth-restricted newborns and its relationship with fetal growth. Eur J Endocrinol 2011; 164: 45-52.
83. Ortiz-Muñoz G, Lopez-Parra V, Lopez-Franco O, et al. Suppressors of cytokine signaling abrogate diabetic nephropathy. J Am Soc Nephrol 2010; 21: 763-772.
84. Shi Y, Du C, Zhang Y, et al. Suppressor of cytokine signaling-1 ameliorates expression of MCP-1 in diabetic nephropathy. Am J Nephrol 2010; 31: 380-388.
85. Isshiki K, He Z, Maeno Y, et al. Insulin regulates SOCS2 expression and the mitogenic effect of IGF-1 in mesangial cells. Kidney Int 2008; 74: 1434-1443.
86. Ko HJ, Zhang Z, Jung DY, et al. Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart. Diabetes 2009; 58: 2536-2546.
87. DeFronzo RA, Tripathy D, Schwenke DC, et al. ACT NOW Study: pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364: 1104-1115.
88. Chatterjee PK. Hepatic inflammation and insulin resistance in pre-diabetes - further evidence for the beneficial actions of PPAR-gamma agonists and a role for SOCS-3 modulation. Br J Pharmacol 2010; 160: 1889-1891.
89. Collino M, Aragno M, Castiglia S, et al. Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. Br J Pharmacol 2010; 160: 1892-1902.
90. Aoyama T, Ikejima K, Kon K, Okumura K, Arai K, Watanabe S. Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice. Hepatology 2009; 49: 1636-1644.
91. Kanatani Y, Usui I, Ishizuka K, et al. Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression. Diabetes 2007; 56: 795-803.
92. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 2003; 311: 372-379.
93. Li P, Xu X, Zheng Z, Zhu B, Shi Y, Liu K. Protective effects of rosiglitazone on retinal neuronal damage in diabetic rats. Curr Eye Res 2011; 36: 673-679.
94. Rodríguez-Calvo R, Serrano L, Coll T, et al. Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2. Diabetes 2008; 57: 2149-2157.
95. Serrano-Marco L, Rodríguez-Calvo R, El Kochairi I, et al. Activation of peroxisome proliferator-activated receptor-β/-δ (PPAR-β/-δ) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes. Diabetes 2011; 60: 1990-1999.
96. Collino M, Benetti E, Miglio G, et al. Peroxisome proliferator-activated receptor β/δ agonism protects the kidney against ischemia/reperfusion injury in diabetic rats. Free Radic Biol Med 2011; 50: 345-353.
97. Chaudhuri A, Ghanim H, Vora M, et al. Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab 2012; 97: 198-207.
98. Pinto Lde F, Compri CM, Fornari JV, et al. The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice. Liver Int 2010; 30: 603-610.
99. McCall KD, Holliday D, Dickerson E, et al. Phenylmethimazole blocks palmitate-mediated induction of inflammatory cytokine pathways in 3T3L1 adipocytes and RAW 264.7 macrophages. J Endocrinol 2010; 207: 343-353.
100. Kim JH, Yoon MS, Chen J. Signal transducer and activator of transcription 3 (STAT3) mediates amino acid inhibition of insulin signaling through serine 727 phosphorylation. J Biol Chem 2009; 284: 35425-35432.
101. Kuppan G, Balasubramanyam J, Monickaraj F, Srinivasan G, Mohan V, Balasubramanyam M. Transcriptional regulation of cytokines and oxidative stress by gallic acid in human THP-1 monocytes. Cytokine 2010; 49: 229-234.
102. He HJ, Zhu TN, Xie Y, et al. Pyrrolidine dithiocarbamate inhibits interleukin-6 signaling through impaired STAT3 activation and association with transcriptional coactivators in hepatocytes. J Biol Chem 2006; 281: 31369-31379.
103. Zauli G, Toffoli B, di Iasio MG, Celeghini C, Fabris B, Secchiero P. Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes. Diabetes 2010; 59: 1261-1265.
104. Lv N, Kim EK, Song MY, et al. JANEX-1, a JAK3 inhibitor, protects pancreatic islets from cytokine toxicity through downregulation of NF-kappaB activation and the JAK/STAT pathway. Exp Cell Res 2009; 315: 2064-2071.
105. Balasubramanyam M, Sampathkumar R, Mohan V. Is insulin signaling molecules misguided in diabetes for ubiquitin-proteasome mediated degradation? Mol Cell Biochem 2005; 275: 117-125.
106. Carper MJ, Cade WT, Cam M, et al. HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 2008; 294: E558-567.